SG11201907422RA - Anti-tau antibodies and methods of use thereof - Google Patents

Anti-tau antibodies and methods of use thereof

Info

Publication number
SG11201907422RA
SG11201907422RA SG11201907422RA SG11201907422RA SG11201907422RA SG 11201907422R A SG11201907422R A SG 11201907422RA SG 11201907422R A SG11201907422R A SG 11201907422RA SG 11201907422R A SG11201907422R A SG 11201907422RA SG 11201907422R A SG11201907422R A SG 11201907422RA
Authority
SG
Singapore
Prior art keywords
therapeutics
floor
denali
south san
california
Prior art date
Application number
SG11201907422RA
Inventor
Xiaocheng Chen
Mark S Dennis
Lesley Ann Kane
Do Jin Kim
Joseph W Lewcock
Suresh Poda
Rishi Rakhit
Rinkan Shukla
Adam P Silverman
Original Assignee
Denali Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Denali Therapeutics Inc filed Critical Denali Therapeutics Inc
Publication of SG11201907422RA publication Critical patent/SG11201907422RA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 23 August 2018 (23.08.2018) WIP0 I PCT 0111111010 0111 °nolo III OH VIII VIII ioluo oimIE (10) International Publication Number WO 2018/152359 Al W O 20 18/ 15 235 9 Al (51) International Patent Classification: C07K 16/18 (2006.01) A61P 25/28 (2006.01) (21) International Application Number: PCT/US2018/018415 (22) International Filing Date: 15 February 2018 (15.02.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/460,642 17 February 2017 (17.02.2017) US 62/583,400 08 November 2017 (08.11.2017) US (71) Applicant: DENALI THERAPEUTICS INC. [US/US]; 151 Oyster Point Blvd., 2nd Floor, South San Francisco, California 94080 (US). (72) Inventors: CHEN, Xiaocheng; c/o Denali Therapeutics Inc., 151 Oyster Point Blvd., 2nd Floor, South San Francis- co, California 94080 (US). DENNIS, Mark S.; c/o Denali Therapeutics Inc., 151 Oyster Point Blvd., 2nd Floor, South San Francisco, California 94080 (US). KANE, Lesley Ann; c/o Denali Therapeutics Inc., 151 Oyster Point Blvd., 2nd Floor, South San Francisco, CA 94080 (US). KIM, Do Jin; c/o Denali Therapeutics Inc., 151 Oyster Point Blvd., 2nd Floor, South San Francisco, California 94080 (US). LEW- COCK, Joseph W.; c/o Denali Therapeutics Inc., 151 Oys- ter Point Blvd., 2nd Floor, South San Francisco, Califor- nia 94080 (US). PODA, Suresh; c/o Denali Therapeutics Inc., 151 Oyster Point Blvd., 2nd Floor, South San Fran- cisco, California 94080 (US). RAKHIT, Rishi; c/o De- nali Therapeutics Inc., 151 Oyster Point Blvd., 2nd Floor, South San Francisco, California 94080 (US). SHUKLA, Rinkan; c/o Denali Therapeutics Inc., 151 Oyster Point Blvd., 2nd Floor, South San Francisco, California 94080 (US). SILVERMAN, Adam P.; c/o Denali Therapeutics Inc., 151 Oyster Point Blvd., 2nd Floor, South San Francis- co, California 94080 (US). (74) Agent: FLANAGAN, Lisa Dornbach et al.; Kilpatrick Townsend & Stockton LLP, Mailstop: IP Docketing - 22, 1100 Peachtree Street, Suite 2800, Atlanta, Georgia 30309 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: with international search report (Art. 21(3)) before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) with sequence listing part of description (Rule 5.2(a)) (54) Title: ANTI-TAU ANTIBODIES AND METHODS OF USE THEREOF (57) : In one aspect, antibodies that specifically bind to a human Tau protein are provided. In some embodiments, an anti-Tau antibody recognizes an epitope within residues 111-125 of full-length human Tau, an epitope within residues 251-270 and/or residues 346-360 of full-length human Tau, or an epitope within residues 186-205 of full-length human Tau. In some embodiments, an anti-Tau antibody specifically binds to phosphorylated human Tau, unphosphorylated human Tau, and/or multiple splice isoforms of human Tau. An anti-Tau antibody disclosed herein may also include one or two modified Fc polypeptides.
SG11201907422RA 2017-02-17 2018-02-15 Anti-tau antibodies and methods of use thereof SG11201907422RA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762460642P 2017-02-17 2017-02-17
US201762583400P 2017-11-08 2017-11-08
PCT/US2018/018415 WO2018152359A1 (en) 2017-02-17 2018-02-15 Anti-tau antibodies and methods of use thereof

Publications (1)

Publication Number Publication Date
SG11201907422RA true SG11201907422RA (en) 2019-09-27

Family

ID=61563475

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201907422RA SG11201907422RA (en) 2017-02-17 2018-02-15 Anti-tau antibodies and methods of use thereof

Country Status (14)

Country Link
US (1) US11370832B2 (en)
EP (1) EP3583123A1 (en)
JP (1) JP2020508054A (en)
KR (1) KR20190134997A (en)
CN (1) CN110520440A (en)
AU (1) AU2018221049A1 (en)
BR (1) BR112019017021A2 (en)
CA (1) CA3053379A1 (en)
IL (1) IL268658A (en)
MA (1) MA47499A (en)
MX (1) MX2019009817A (en)
SG (1) SG11201907422RA (en)
TW (1) TW201843175A (en)
WO (1) WO2018152359A1 (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2902026C (en) 2013-03-13 2023-08-29 Prothena Biosciences Limited Tau immunotherapy
DK3452507T3 (en) 2016-05-02 2022-11-14 Prothena Biosciences Ltd TAU IMMUNOTHERAPY
WO2017191560A1 (en) 2016-05-02 2017-11-09 Prothena Biosciences Limited Antibodies recognizing tau
PL3583120T3 (en) 2017-02-17 2023-01-09 Denali Therapeutics Inc. Engineered transferrin receptor binding polypeptides
EP3692070A1 (en) * 2017-10-02 2020-08-12 Denali Therapeutics Inc. Fusion proteins comprising enzyme replacement therapy enzymes
BR112020007536A2 (en) * 2017-10-16 2020-09-29 Eisai R&D Management Co., Ltd. anti-tau antibodies and their uses
WO2019094576A1 (en) * 2017-11-08 2019-05-16 Denali Therapeutics Inc. Bace-tau bispecific antibodies
WO2019094608A1 (en) 2017-11-08 2019-05-16 Denali Therapeutics Inc. Anti-bace1 antibodies and methods of use thereof
BR112021002730A2 (en) * 2018-08-16 2021-08-10 Denali Therapeutics Inc. engineered bispecific proteins
KR20210074279A (en) * 2018-08-22 2021-06-21 데날리 테라퓨틱스 인크. Anti-HER2 polypeptides and methods of use thereof
SG11202108414UA (en) 2019-03-03 2021-08-30 Prothena Biosciences Ltd Antibodies recognizing tau
AU2020283534A1 (en) * 2019-05-31 2021-11-25 Eli Lilly And Company Compounds and methods targeting human tau
GB2585252A (en) 2019-07-05 2021-01-06 Gen2 Neuroscience Ltd Tau epitope and binding molecules
CA3165846A1 (en) 2019-12-23 2021-07-01 Denali Therapeutics Inc. Progranulin variants
CN114930170A (en) 2020-01-02 2022-08-19 豪夫迈·罗氏有限公司 Method for determining the amount of therapeutic antibody in the brain
KR20220131246A (en) * 2020-01-13 2022-09-27 데날리 테라퓨틱스 인크. Anti-TREM2 antibodies and methods of use thereof
JP2023545707A (en) 2020-10-14 2023-10-31 デナリ セラピューティクス インコーポレイテッド Fusion protein containing sulfoglucosamine sulfohydrolase enzyme and method thereof
WO2023041805A1 (en) 2021-09-20 2023-03-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for improving the efficacy of hdac inhibitor therapy and predicting the response to treatment with hdac inhibitor

Family Cites Families (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993008302A1 (en) * 1991-10-25 1993-04-29 Itt Automotive Europe Gmbh Monoclonal antibodies directed against the microtubule-associated protein tau
EP1535930B1 (en) 2002-08-14 2010-10-06 Mitsubishi Chemical Medience Corporation Antibody specific to central nervous system tau protein
WO2005062977A2 (en) 2003-12-23 2005-07-14 The Regents Of The University Of California Prostate cancer specific internalizing human antibodies
US7456027B2 (en) 2004-04-15 2008-11-25 University Of Florida Research Foundation, Inc. Proteolytic biomarkers for traumatic injury to the nervous system
US7435804B2 (en) * 2004-10-19 2008-10-14 Phage Biotechnology, Inc. Method for obtaining single chain antibodies to human interferon α2b
MX2008012023A (en) 2006-03-21 2008-10-01 Wyeth Corp Methods for preventing and treating amyloidogenic diseases.
US8012936B2 (en) * 2006-03-29 2011-09-06 New York University Tau fragments for immunotherapy
KR101735257B1 (en) 2007-01-05 2017-05-12 유니버시티 오브 취리히 Method of providing disease-specific binding molecules and targets
WO2011133919A1 (en) 2010-04-22 2011-10-27 Janssen Alzheimer Immunotherapy Use of tau to monitor immunotherapy
US9605054B2 (en) 2009-02-23 2017-03-28 The Board Of Trustees Of The University Of Illinois Composition and method for treating a tauopathy
WO2010136508A2 (en) 2009-05-28 2010-12-02 Glaxo Group Limited Stem cell targeting
US8609097B2 (en) * 2009-06-10 2013-12-17 Hoffmann-La Roche Inc. Use of an anti-Tau pS422 antibody for the treatment of brain diseases
EP3329932A1 (en) 2009-06-10 2018-06-06 New York University Immunological targeting of pathological tau proteins
US20170315136A9 (en) 2009-06-19 2017-11-02 Banyan Biomarkers, Inc. Biomarker assay of neurological condition
WO2011026031A1 (en) 2009-08-28 2011-03-03 The Board Of Regents Of The University Of Texas System Antibodies that bind tau oligomers
US10266585B2 (en) 2009-08-28 2019-04-23 The Board Of Regents Of The Univerity Of Texas System Methods of treating brain injury
EP2478360B1 (en) 2009-09-14 2018-06-27 Banyan Biomarkers, Inc. Autoantibody markers for diagnosis of traumatic brain injury
ES2548686T3 (en) 2010-10-07 2015-10-20 Ac Immune S.A. Antibodies that recognize phospho-Tau
PT2627672T (en) * 2010-10-11 2018-11-16 Univ Zuerich Human anti-tau antibodies
EP2670434B1 (en) * 2011-01-31 2018-12-26 Tau Bio-Logic Corp. Treatment of tauopathies
JP6457263B2 (en) 2011-05-20 2019-01-23 オリゴメリックス インコーポレイテッド Tau protease composition and methods of use
GB201111361D0 (en) 2011-07-04 2011-08-17 Nordic Bioscience As Biochemical markers for neurodegenerative conditions
GB201112056D0 (en) 2011-07-14 2011-08-31 Univ Leuven Kath Antibodies
PL2748201T3 (en) 2011-08-23 2018-04-30 Roche Glycart Ag Bispecific t cell activating antigen binding molecules
SG11201400125RA (en) 2011-09-19 2014-03-28 Axon Neuroscience Se Protein-based therapy and diagnosis of tau-mediated pathology in alzheimer's disease
US9540434B2 (en) 2011-10-07 2017-01-10 Ac Immune S.A. Phosphospecific antibodies recognising tau
SI2794654T1 (en) 2011-12-20 2019-08-30 Janssen Biotech, Inc. Anti-phf-tau antibodies and their uses
MX356800B (en) 2012-04-05 2018-06-13 Ac Immune Sa Humanized tau antibody.
KR102133610B1 (en) 2012-05-31 2020-07-14 고리쓰다이가쿠호진 오사카 시리쓰다이가쿠 Therapeutic agent or prophylactic agent for dementia
KR102494798B1 (en) * 2012-07-03 2023-02-06 워싱턴 유니버시티 Antibodies to tau
CA2882034C (en) 2012-08-16 2019-10-29 Ipierian, Inc. Methods of treating a tauopathy
AU2013328881B2 (en) 2012-10-12 2018-03-15 Arizona Board Of Regents, On Behalf Of Arizona State University Antibody based reagents that specifically recognize toxic oligomeric forms of tau
US9200068B2 (en) 2012-12-18 2015-12-01 Regents Of The University Of Minnesota Compositions and methods related to tauopathy
US9598484B2 (en) 2012-12-21 2017-03-21 Biogen Ma Inc. Human anti-tau antibodies
US8980270B2 (en) 2013-01-18 2015-03-17 Ipierian, Inc. Methods of treating a tauopathy
CA2902026C (en) 2013-03-13 2023-08-29 Prothena Biosciences Limited Tau immunotherapy
WO2014152157A2 (en) 2013-03-15 2014-09-25 Bethisrael Deaconess Medical Center, Inc. Methods and compositions for the generation and use of conformation-specific antibodies
US9598485B2 (en) 2013-03-15 2017-03-21 Ac Immune S.A. Anti-tau antibodies and methods of use
GB201312226D0 (en) * 2013-07-08 2013-08-21 Adx Neurosciences Improved antibodies
US11261262B2 (en) 2013-09-03 2022-03-01 Novimmune Sa Readily isolated bispecific binding molecules with native format having mutated constant regions
EP3074420A2 (en) 2013-11-27 2016-10-05 Ipierian, Inc. Methods of treating a tauopathy
CN106030310B (en) 2013-12-13 2019-01-04 通用医疗公司 Soluble high-molecular amount (HMW) TAU type and its application
PL3083680T3 (en) 2013-12-20 2020-06-29 F. Hoffmann-La Roche Ag Humanized anti-tau(ps422) antibodies and methods of use
EP2899208A1 (en) 2014-01-28 2015-07-29 F.Hoffmann-La Roche Ag Camelid single-domain antibody directed against phosphorylated tau proteins and methods for producing conjugates thereof
AU2015213735A1 (en) 2014-02-10 2016-08-04 Merck Sharp & Dohme Corp. Antibodies that bind to human Tau and assay for quantifying human Tau using the antibodies
EP3104870A4 (en) 2014-02-14 2017-09-13 Ipierian, Inc. Tau peptides, anti-tau antibodies, and methods of use thereof
BR112016016274A2 (en) 2014-02-19 2017-10-03 Hoffmann La Roche BLOOD-BRAIN BARRIER BRIDGE
NZ727024A (en) 2014-06-26 2022-02-25 Janssen Vaccines & Prevention Bv Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau
AR100978A1 (en) 2014-06-26 2016-11-16 Hoffmann La Roche ANTI-Tau HUMANIZED ANTIBODY BRAIN LAUNCHERS (pS422) AND USES OF THE SAME
TWI664190B (en) 2014-06-27 2019-07-01 美商Ｃ２Ｎ醫療診斷有限責任公司 Humanized anti-tau antibodies
JP6913018B2 (en) 2014-07-08 2021-08-04 ニューヨーク・ユニバーシティ Tau imaging ligands, and their use in the diagnosis and treatment of tau disorders
DE102014013571A1 (en) 2014-09-18 2016-03-24 Aj Roboscreen Gmbh Monoclonal antibody to human TAU protein
CA3001724A1 (en) 2014-10-10 2016-04-14 National Research Council Of Canada Anti-tau antibody and uses thereof
US10323082B2 (en) 2014-10-14 2019-06-18 The Research Foundation For Mental Hygiene, Inc. Treatment of tauopathies by passive immunization targeting the N-terminal projection domain of tau
PL3221349T3 (en) * 2014-11-19 2021-05-17 Axon Neuroscience Se Humanized tau antibodies in alzheimer's disease
WO2016112078A2 (en) 2015-01-08 2016-07-14 Janssen Biotech, Inc. Anti-phf-tau antibodies and their uses
MA41451A (en) 2015-02-04 2017-12-12 Univ Washington ANTI-TAU CONSTRUCTIONS
CA2977648C (en) 2015-02-24 2024-01-02 Rpeptide, Llc Anti-tau antibodies
TWI669314B (en) 2015-02-26 2019-08-21 美國禮來大藥廠 Antibodies to tau and uses thereof
EP3303386A1 (en) * 2015-06-05 2018-04-11 Genentech, Inc. Anti-tau antibodies and methods of use
JP6619460B2 (en) 2015-06-24 2019-12-11 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Humanized anti-tau (pS422) antibodies and methods of use
CN108282997B (en) 2015-06-25 2020-12-25 肌肉骨骼科学教育研究所有限公司 Intervertebral fusion device and system for implantation
TN2017000539A1 (en) 2015-07-06 2019-04-12 Ucb Biopharma Sprl Tau-binding antibodies
MX2017015908A (en) 2015-07-06 2018-03-15 Ucb Biopharma Sprl Tau-binding antibodies.
WO2017011556A1 (en) 2015-07-13 2017-01-19 The General Hospital Corporation Rare phosphorylated high molecular weight (hmw) tau species that are involved in neuronal uptake and propagation and applications thereof
JO3711B1 (en) 2015-07-13 2021-01-31 H Lundbeck As Antibodies specific for hyperphosphorylated tau and methods of use thereof
WO2017027691A1 (en) 2015-08-13 2017-02-16 New York University Antibody-based molecules selective for the {p}ser404 epitope of tau and their uses in the diagnosis and treatment of tauopathy
JP6913078B2 (en) 2015-08-13 2021-08-04 ニューヨーク・ユニバーシティ Antibody-based molecules specific for the shortened Asp421 epitope of tau, and their use in the diagnosis and treatment of tau dysfunction.
EP3359569A2 (en) 2015-10-06 2018-08-15 Alector LLC Anti-trem2 antibodies and methods of use thereof
US20170138400A1 (en) 2015-11-12 2017-05-18 Schaeffler Technologies AG & Co. KG Bainite hardened stack bearing
US20190010504A1 (en) 2015-12-11 2019-01-10 Arizona Board Of Regents On Behalf Of Arizona State University Human alzheimer's disease and traumatic brain injury associated tau variants as biomarkers and methods of use thereof
WO2017191560A1 (en) 2016-05-02 2017-11-09 Prothena Biosciences Limited Antibodies recognizing tau
AU2017259039A1 (en) 2016-05-02 2018-10-11 Prothena Biosciences Limited Antibodies recognizing tau
DK3452507T3 (en) 2016-05-02 2022-11-14 Prothena Biosciences Ltd TAU IMMUNOTHERAPY
WO2017194589A1 (en) 2016-05-10 2017-11-16 Vib Vzw Inhibition of tau-mediated early synaptic dysfunction
EP3878864A1 (en) 2016-07-12 2021-09-15 H. Lundbeck A/S Antibodies specific for hyperphosphorylated tau and methods of use thereof
EP3487524A4 (en) 2016-07-20 2020-03-25 Anahit Ghochikyan Humanized anti-tau antibodies and compositions for and methods of making and using in treatment, diagnosis and monitoring of tauopathies
US10870709B2 (en) 2016-07-22 2020-12-22 New York University Specific murine and humanized monoclonal antibodies detecting pathology associated secondary structure changes in proteins and peptides
WO2018031361A2 (en) 2016-08-09 2018-02-15 Eli Lilly And Company Combination therapy
US11072639B2 (en) 2016-09-08 2021-07-27 Regenerative Research Foundation Bi-functional anti-tau polypeptides and use thereof
FR3058143B1 (en) 2016-10-27 2021-03-12 Univ Grenoble Alpes ANTI-TAU NANOCBODIES
WO2018085653A1 (en) 2016-11-04 2018-05-11 The Regents Of The University Of California Compositions targeting 3-repeat tau for the treatment of neurodegenerative disorders, and methods for making and using them
US9914781B1 (en) * 2016-11-08 2018-03-13 Glaxosmithkline Intellectual Property Development Limited Binding agonist for treatment of neurological and other disorders
KR20240035636A (en) 2016-12-07 2024-03-15 제넨테크, 인크. Anti-tau antibodies and methods of their use
CR20230163A (en) 2016-12-07 2023-07-06 Genentech Inc Anti-tau antibodies and methods of use
MA47205A (en) 2017-01-04 2019-11-13 H Lundbeck As SPECIFIC ANTIBODIES OF HYPERPHOSPHORYLATED TAU PROTEIN TO TREAT EYE DISEASES
JOP20180014A1 (en) 2017-02-27 2019-01-30 Teijin Pharma Ltd Humanized antibody for treating or preventing cognitive disorders, process for producing the same, and agent for treating or preventing cognitive disorders using the same
JOP20180021A1 (en) 2017-03-16 2019-01-30 Janssen Biotech Inc Anti-phf-tau antibodies and uses thereof
CN110418804A (en) 2017-03-28 2019-11-05 扬森疫苗与预防公司 The binding molecule specifically combined with tau
SG10202110737WA (en) 2017-03-28 2021-11-29 Janssen Vaccines & Prevention Bv Methods for detection of tau protein aggregation modulating compounds
TW202400231A (en) 2017-03-28 2024-01-01 美商建南德克公司 Methods of treating neurodegenerative diseases
EP3601325B1 (en) 2017-03-28 2023-07-19 INSERM (Institut National de la Santé et de la Recherche Médicale) New tau species
EP3619233A4 (en) 2017-05-02 2021-03-03 Prothena Biosciences Limited Antibodies recognizing tau
EA202090063A1 (en) 2017-06-16 2020-04-03 Бристоль-Мейерз Сквибб Компани COMPOSITIONS AND METHODS FOR TREATMENT OF TAUPATHIA
US10662246B2 (en) 2017-07-10 2020-05-26 New York University Monoclonal antibody to treat alzheimer's disease, prion disease, frontotemporal dementias and traumatic brain injury/chronic traumatic encephalopathy
ES2965049T3 (en) 2017-07-12 2024-04-10 Dana Farber Cancer Inst Inc Compounds for the degradation of tau protein
WO2019028191A1 (en) 2017-08-01 2019-02-07 Amgen Inc. Systems and methods for performing a real-time glycan assay of a sample
BR112020007536A2 (en) 2017-10-16 2020-09-29 Eisai R&D Management Co., Ltd. anti-tau antibodies and their uses
WO2019094576A1 (en) 2017-11-08 2019-05-16 Denali Therapeutics Inc. Bace-tau bispecific antibodies

Also Published As

Publication number Publication date
KR20190134997A (en) 2019-12-05
JP2020508054A (en) 2020-03-19
CN110520440A (en) 2019-11-29
EP3583123A1 (en) 2019-12-25
US20200216522A1 (en) 2020-07-09
WO2018152359A1 (en) 2018-08-23
AU2018221049A1 (en) 2019-09-19
MA47499A (en) 2019-12-25
US11370832B2 (en) 2022-06-28
IL268658A (en) 2019-10-31
TW201843175A (en) 2018-12-16
CA3053379A1 (en) 2018-08-23
MX2019009817A (en) 2019-11-21
BR112019017021A2 (en) 2020-04-14

Similar Documents

Publication Publication Date Title
SG11201907422RA (en) Anti-tau antibodies and methods of use thereof
SG11201907427YA (en) Engineered transferrin receptor binding polypeptides
SG11201809381XA (en) Polynucleotides encoding interleukin-12 (il12) and uses thereof
SG11201809336QA (en) Anti-pd-l1 antibodies
SG11201805709RA (en) Anti-pro/latent myostatin antibodies and methods of use thereof
SG11201805532XA (en) Multivalent and multispecific 41bb-binding fusion proteins
SG11201807279QA (en) Binding proteins and methods of use thereof
SG11201903359RA (en) Bispecific antibody against bcma and cd3 and an immunological drug for combined use in treating multiple myeloma
SG11201907419PA (en) Transferrin receptor transgenic models
SG11201903857UA (en) Antibodies to pd-1 and uses thereof
SG11201804673WA (en) Novel anti-claudin antibodies and methods of use
SG11201807401RA (en) Therapeutic membrane vesicles
SG11201805422WA (en) Multivalent and multispecific ox40-binding fusion proteins
SG11201810023QA (en) Anti-tim-3 antibodies and methods of use thereof
SG11201804178YA (en) Pd1 and/or lag3 binders
SG11201806496SA (en) Antigen binding proteins that bind pd-l1
SG11201804134YA (en) Fgfr2 inhibitors alone or in combination with immune stimulating agents in cancer treatment
SG11201811424PA (en) Mirrored token vault
SG11201901020RA (en) Anti-siglec-7 antibodies for the treatment of cancer
SG11201907889YA (en) Glycan-interacting compounds and methods of use
SG11201908051RA (en) Modified human igm constant regions for modulation of complement-dependent cytolysis effector function
SG11201903693QA (en) Polypeptide variants and uses thereof
SG11201810927QA (en) Pd-l1-specific antibodies and methods of using the same
SG11201809374VA (en) Cd40l-fc fusion polypeptides and methods of use thereof
SG11201809620UA (en) The contorsbody - a single chain target binder